Pharvaris (NASDAQ:PHVS - Get Free Report)'s stock price rose 5.3% on Tuesday . The company traded as high as $19.84 and last traded at $19.34. Approximately 6,321 shares were traded during trading, a decline of 86% from the average daily volume of 46,693 shares. The stock had previously closed at $18.36.
The firm's 50 day moving average price is $19.42 and its two-hundred day moving average price is $19.33. The stock has a market cap of $1.01 billion, a PE ratio of -6.91 and a beta of -3.06.
Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Pharvaris during the 3rd quarter valued at $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pharvaris in the third quarter valued at about $906,000. State Street Corp purchased a new stake in Pharvaris in the 3rd quarter worth approximately $1,000,000. Geode Capital Management LLC increased its position in Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock valued at $685,000 after purchasing an additional 5,753 shares during the period. Finally, Novo Holdings A S grew its stake in shares of Pharvaris by 47.7% in the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company's stock worth $32,430,000 after buying an additional 556,970 shares during the last quarter.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.